Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358373 | 1.00 | PREP (0.57) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL20654187 | 0.92 | PREP (0.61) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL20653871 | 0.92 | PREP (0.61) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL28026781 | 0.83 | MEN1 (0.53) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL15817600 | 0.81 | PREP (0.58) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL31158205 | 0.81 | MEN1 (0.51) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL30580148 | 0.81 | MEN1 (0.51) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL23358427 | 0.81 | PREP (0.50) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL12248054 | 0.80 | PREP (0.52) | PREPMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL31552122 | 0.80 | MEN1 (0.50) | PREPMEN1KMT2ANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034027-B2 | Fused heterocyclic derivatives as phosphodiesterase inhibitors | LILLY ICOS LLC (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050234065-A1 | Dipeptidyl peptidase-IV inhibitors | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| US-20030207867-A1 | Fused heterocyclic derivatives as phosphodiesterase inhibitors | LILLY ICOS LLC, A DELAWARE CORPORATION | 2003-11-06 | — | — | US | disclosed |
| EP-1305313-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Lilly Icos LLC (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010166-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LILLY ICOS LLC (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207867-A1 | Fused heterocyclic derivatives as phosphodiesterase inhibitors | PDE3A, PDE3B, PDE2A | PREP 205/4885MEN1 1628/4885KMT2A 4024/4885 |
| US-20050234065-A1 | Dipeptidyl peptidase-IV inhibitors | ALPI, DPP4, SI | PREP 62/4885MEN1 1706/4885KMT2A 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.